Additionally, in this setting, we would expect enhanced DNA damage, particularly in conjunction with RT and TMZ chemotherapy, which may explain why our patient with a mutant IDH1 GBM responded so favorably to this therapy, especially if DNA repair machinery in the IDH-mutant tumor is impaired. The gene discussed is IDH2; the disease is glioblastoma.